Asia Green Biotechnology Corp. Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order
Asia Green Biotechnology Corp. Announces Delay in Filing of Annual Financial Statements and Application for Management Cease Trade Order
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE OR FOR DISSEMINATION IN THE UNITED STATES
不用於分發給美國新聞通訊社或在美國傳播
CALGARY, AB / ACCESSWIRE / April 17, 2024 / Asia Green Biotechnology Corp. ("Asia Green" or the "Company")
(CSE:ASIA) announces that it is unlikely to meet the filing date of April 29, 2024 ("Filing Date"),
as required under National Instrument 51-102, for filing of the following continuous disclosure documents (collectively, the "Documents"):
艾伯塔省卡爾加里/ACCESSWIRE/2024年4月17日/亞洲綠色生物技術公司（“Asia Green” 或 “公司”）
（CSE: ASIA）宣佈，它不太可能在2024年4月29日的申請日期（“申請日期”）之前完成，
根據國家儀器51-102的要求，提交以下持續披露文件（統稱爲 “文件”）：
- The Company's Annual Audited Financial Statements for the year ended December 31, 2023,
as required by section 4.2 of National Instrument 51-102 - Continuous Disclosure Obligations
("NI 51-102"); and - The Company's Management Discussion & Analysis for the year ended December 31, 2023,
as required by section 5.1(2) of NI 51-102. - CEO and CFO certificates relating to the Audited Annual Financial Statements, as required by
NI 51-102.
- 公司截至2023年12月31日止年度的年度經審計的財務報表，
按照《國家儀器》51-102 第 4.2 節的要求- 持續披露義務
（“NI 51-102”）；以及 - 公司截至2023年12月31日止年度的管理層討論與分析，
按照 NI 51-102 第 5.1 (2) 節的要求。 - 根據要求，與經審計的年度財務報表相關的首席執行官和首席財務官證書
在 51-102 年。
The potential default is due, in part, to business and administrative disruption experienced by the Company in respect of the Company's auditor's inability to complete the work required to issue the Documents as a result of an investigation of the former auditor's activities on matters unrelated to the Company.
潛在的違約在一定程度上是由於對前核數師在與公司無關的事項上的活動進行調查後，公司的核數師無法完成發佈文件所需的工作，因此公司遭受了業務和管理混亂。
The Company has now engaged new auditors to complete the work and it is expected the Documents will be filed within 30-60 days of the Filing Date, if not before.
該公司現已聘請了新的核數師來完成工作，預計文件將在提交日期後的30-60天內提交，如果不是在此之前。
Accordingly, and as a precautionary measure, the Company has applied to the Alberta Securities Commission ("ASC") for a Management Cease Trade Order ("MCTO")that will prohibit the management of the Company from trading in the securities of the Company until such time as the Documents are filed. No decision has yet been made by the ASC on this application. The ASC may grant the application and issue the MCTO or it may impose an issuer cease trade order if the Documents are not filed in a timely fashion.
因此，作爲預防措施，公司已向艾伯塔省證券委員會（“ASC”）申請管理停止交易令（“MCTO”），該令將禁止公司管理層在文件提交之前交易公司的證券。澳大利亞證券交易委員會尚未就該申請做出任何決定。如果文件未及時提交，澳大利亞證券交易委員會可以批准申請並簽發MCTO，也可以下達發行人停止交易令。
During any period of default and until filing of the Documents, the Company intends to satisfy the provisions of the alternative information guidelines as required by National Policy 12-203 Management Cease Trade Orders.
在任何違約期間以及在提交文件之前，公司都打算按照國家政策12-203的要求滿足替代信息指南的規定 管理層停止交易訂單。
Until the Company has filed the Documents, members of the Company's management and other insiders are subject to an insider trading black-out policy as per its internal Insider Trading Policy that is consistent with the principles in Section 9 of National Policy 11-207 - Failure-to-File Cease Trade Orders and Revocations in Multiple Jurisdictions. The Company confirms that, other than as disclosed in prior press releases and material change reports, there have been no material business developments since the filing on November 29, 2023 of the Company's latest interim financial reports for the period ended September 30, 2023.
在公司提交文件之前，根據其內部內幕交易政策，公司管理層成員和其他內部人士將受到內幕交易封鎖政策的約束，該政策符合國家政策11-207第9節中的原則- 未能在多個司法管轄區提交停止貿易令和撤銷令。公司證實，除了先前的新聞稿和重大變動報告中披露的內容外，自2023年11月29日公司提交截至2023年9月30日的最新中期財務報告以來，沒有任何重大的業務發展。
For further information, contact:
欲了解更多信息，請聯繫：
Asia Green Biotechnology Corp.
David E.T. Pinkman (CEO)
T: 403 863-6034
E: david.pinkman@asiagreenbiotechnology.com
亞洲綠色生物技術公司
大衛 E.T. Pinkman（首席執行官）
電話：403 863-6034
E: david.pinkman@asiagreenbiotechnology.com
Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
CSE及其監管服務提供商（該術語在CSE的政策中定義）均不對本新聞稿的充分性或準確性承擔責任。
Caution Regarding Forward-Looking Information Forward-looking statements - Certain information set forth in this news release may contain forward-looking statements that involve substantial known and unknown risks and uncertainties. Forward-looking statements are often, but not always, identified by words such as "believes", "may", "likely", "plans", or similar words. Forward- looking statements included in this news release include statements with respect to activities in Zimbabwe. These forward-looking statements are subject to numerous risks and uncertainties, certain of which are beyond the control of the Company, including, but not limited to the impact of general economic conditions, industry conditions, currency fluctuations, and dependence upon regulatory approvals. The Company does not assume any obligation to update the forward-looking statements to reflect changes in assumptions or circumstances other than as required by applicable law.
前瞻性信息注意前瞻性陳述——本新聞稿中列出的某些信息可能包含涉及大量已知和未知風險和不確定性的前瞻性陳述。前瞻性陳述通常以 “相信”、“可能”、“可能”、“計劃” 或類似詞語來識別，但並非總是如此。本新聞稿中包含的前瞻性聲明包括有關津巴布韋活動的聲明。這些前瞻性陳述受到許多風險和不確定性的影響，其中一些風險和不確定性是公司無法控制的，包括但不限於總體經濟狀況、行業狀況、貨幣波動和對監管批准的依賴的影響。除適用法律要求外，公司不承擔任何義務更新前瞻性陳述以反映假設或情況的變化。
SOURCE: Asia Green Biotechnology Corp.
來源：亞洲綠色生物技術公司
譯文內容由第三人軟體翻譯。